Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla")announced the launch of Li...
New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Ges...
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announced that it has received appro...
Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commerc...
As life sciences companies scale biologics, advanced therapies, and personalized medicines, sustainability has moved from aspiration to operational imperat...
As biologic modalities grow more complex and timelines compress, the operational relationship between contract development and manufacturing organizations ...
New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization...
Charles River Laboratories has raised its 2026 profit forecast following a strategic divestiture of non-core and underperforming assets, ...
First Investigational Gene Therapy for Pitt Hopkins Syndrome Intended to Address Underlying Disease Biology -- Mahzi Therapeutics Inc., a clinical...
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), see...
Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier Biotech" or "the Company") has entered into an exclusive licensing agreemen...
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced a collaboration with DNAstack to power the wor...
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based thera...
Bayer files false advertising suit against J&J and Janssen Biotech Lawsuit seeks preliminary and permanent injunctions in addition to damages. ...
© 2026 Biopharma Boardroom. All Rights Reserved.
